These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 26424648)
61. [Virological and immunological studies on inapparent Epstein-Barr virus infection in healthy individuals: in comparison to immunosuppressed patients and patients with infectious mononucleosis]. Imai S Hokkaido Igaku Zasshi; 1990 Sep; 65(5):481-92. PubMed ID: 2172132 [TBL] [Abstract][Full Text] [Related]
63. Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. Iwata S; Wada K; Tobita S; Gotoh K; Ito Y; Demachi-Okamura A; Shimizu N; Nishiyama Y; Kimura H J Gen Virol; 2010 Jan; 91(Pt 1):42-50. PubMed ID: 19793909 [TBL] [Abstract][Full Text] [Related]
64. Epstein-Barr virus (EBV)-associated lymphoid lesions of the head and neck. Auerbach A; Aguilera NS Semin Diagn Pathol; 2015 Jan; 32(1):12-22. PubMed ID: 25804341 [TBL] [Abstract][Full Text] [Related]
65. Frequent double infection with Epstein-Barr virus and human herpesvirus-6 in patients with acute infectious mononucleosis. Bertram G; Dreiner N; Krueger GR; Ramon A; Ablashi DV; Salahuddin SZ; Balachandram N In Vivo; 1991; 5(3):271-9. PubMed ID: 1654150 [TBL] [Abstract][Full Text] [Related]
66. [Immunoglobulin M positive for cytomegalovirus and Epstein-Barr virus in a patient with infectious mononucleosis. As we interpret it?]. Peña Irún A; González Santamaría A Semergen; 2012 Oct; 38(7):479. PubMed ID: 23021587 [No Abstract] [Full Text] [Related]
67. Burkitt lymphoma: the role of Epstein-Barr virus revisited. Grömminger S; Mautner J; Bornkamm GW Br J Haematol; 2012 Mar; 156(6):719-29. PubMed ID: 22482131 [No Abstract] [Full Text] [Related]
71. Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults. Grotto I; Mimouni D; Huerta M; Mimouni M; Cohen D; Robin G; Pitlik S; Green MS Epidemiol Infect; 2003 Aug; 131(1):683-9. PubMed ID: 12948368 [TBL] [Abstract][Full Text] [Related]
72. Modelling the dynamics of EBV transmission to inform a vaccine target product profile and future vaccination strategy. Goscé L; Winter JR; Taylor GS; Lewis JEA; Stagg HR Sci Rep; 2019 Jun; 9(1):9290. PubMed ID: 31243321 [TBL] [Abstract][Full Text] [Related]
73. The Status and Prospects of Epstein-Barr Virus Prophylactic Vaccine Development. Sun C; Chen XC; Kang YF; Zeng MS Front Immunol; 2021; 12():677027. PubMed ID: 34168649 [TBL] [Abstract][Full Text] [Related]
74. Epstein-Barr virus: an important vaccine target for cancer prevention. Cohen JI; Fauci AS; Varmus H; Nabel GJ Sci Transl Med; 2011 Nov; 3(107):107fs7. PubMed ID: 22049067 [TBL] [Abstract][Full Text] [Related]
75. Acute hepatitis due to infectious mononucleosis. Manappallil RG; Mampilly N; Josphine B BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31473633 [TBL] [Abstract][Full Text] [Related]
76. Clinical and laboratory characteristics of infectious mononucleosis by Epstein-Barr virus in Mexican children. González Saldaña N; Monroy Colín VA; Piña Ruiz G; Juárez Olguín H BMC Res Notes; 2012 Jul; 5():361. PubMed ID: 22818256 [TBL] [Abstract][Full Text] [Related]
77. Derivation and validation of clinical prediction rules for diagnosis of infectious mononucleosis: a prospective cohort study. de Paor M; Boland F; Cai X; Smith S; Ebell MH; Mac Donncha E; Fahey T BMJ Open; 2023 Feb; 13(2):e068877. PubMed ID: 36849213 [TBL] [Abstract][Full Text] [Related]